Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Actavis Puts Greater Emphasis On Branded Rx By Taking Allergan Name

This article was originally published in The Pink Sheet Daily

Executive Summary

The growing spec pharma has seen a 300% increase in its branded portfolio revenues since the acquisition of Forest and Warner Chilcott and is honoring the new direction by taking on the name of its most recent acquisition.

You may also be interested in...



Actavis Completes Sales Reorganization, Pipeline Rationalization

The company will move forward with 70 pipeline candidates following the closing of the Allergan merger, Senior VP-Brand R&D David Nicholson said during the company’s first quarter earnings call.

With Actavis-Allergan On Track To Close Soon, Saunders Talks Integration

Brent Saunders, who will lead the new Allergan once the merger with Actavis closes, is ready to begin the integration, with an eye toward achieving 80% of the expected $2.3 billion in cost savings 12 months after close.

Actavis Flexes Its Commercial Muscles Ahead Of Allergan Integration

Before adding Allergan into the mix – and taking on its name – Actavis wants to show investors that it has a solid foundation as a growth pharma with strong brands in GI, CNS and women’s health.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS078165

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel